Edgar Filing: MPM BIOVENTURES III QP LP

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â MPM BioVentures IV QP LP

2. Date of Event Requiring Statement (Month/Day/Year)
10/30/2008

3. Issuer Name and Ticker or Trading Symbol
PEPLIN INC [PLIN]

(Last)

(First)

(Middle)

C/O MPM ASSET MANAGEMENT,Â 200 CLARENDON STREET, 54TH FLOOR

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

BOSTON,Â MAÂ 02116

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,281,190	I	See Footnote ⁽¹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock Warrant (Right to Buy)	10/23/2008	10/23/2013	Common Stock	385,885	$ 7.86	I	See Footnote ⁽²⁾
Common Stock Warrant (Right to Buy) ⁽³⁾	06/26/2006	10/30/2010	Common Stock	196,852 ⁽⁴⁾	$ 13.6	I	See Footnote ⁽⁵⁾
Common Stock Warrant (Right to Buy) ⁽³⁾	11/01/2006	10/30/2010	Common Stock	210,937 ⁽⁴⁾	$ 13.6	I	See Footnote ⁽⁶⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
MPM BioVentures IV QP LP C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM BioVentures IV GP LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM BioVentures IV LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM Asset Management Investors BV4 LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM BioVentures IV GmbH & Co. Beteiligungs KG C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM BIOVENTURES III GP LP C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM BIOVENTURES III LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM BIOVENTURES III LP C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM BIOVENTURES III QP LP C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM BIOVENTURES III GMBH & CO. Beteiligungs KG C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â

Signatures

By Vaughn Kailian, member of MPM BioVentures IV LLC, the managing member of MPM BioVentures IV GP LLC, the general partner of MPM BioVentures IV-QP, L.P. /s/ Vaughn Kailian		10/30/2008
^**Signature of Reporting Person		Date
By Vaughn Kailian, member of MPM BioVentures IV LLC, the managing member of MPM BioVentures IV GP LLC /s/ Vaughn Kailian		10/30/2008
^**Signature of Reporting Person		Date
By Vaughn Kailian, member of MPM BioVentures IV LLC /s/ Vaughn Kailian		10/30/2008
^**Signature of Reporting Person		Date
By Vaughn Kailian, member of MPM BioVentures IV LLC, the manager of MPM Asset Management Investors BV4 LLC /s/ Vaughn Kailian		10/30/2008
^**Signature of Reporting Person		Date
By Vaughn M. Kailian, member of MPM BioVentures IV LLC, the managing member of MPM BioVentures IV GP LLC, the managing limited partner of MPM BioVentures IV GmbH & Co. Beteiligungs KG /s/ Vaughn M. Kailian		10/30/2008
^**Signature of Reporting Person		Date
By Luke Evnin, Series A Member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, LP /s/ Luke Evnin		10/30/2008
^**Signature of Reporting Person		Date
By Luke Evnin, Series A Member of MPM BioVentures III LLC /s/ Luke Evnin		10/30/2008
^**Signature of Reporting Person		Date
By Luke Evnin, Series A Member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, LP, the general partner of MPM BioVentures III, LP /s/ Luke Evnin		10/30/2008
^**Signature of Reporting Person		Date
By Luke Evnin, Series A Member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, LP, the general partner of MPM BioVentures III-QP, LP /s/ Luke Evnin		10/30/2008
^**Signature of Reporting Person		Date
By Luke Evnin, Series A Member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, LP, in its capacity as the Managing Limited Partner of MPM BioVentures III GmbH & Co. Beteiligungs KG /s/ Luke Evnin		10/30/2008
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The shares are held as follows: 2,685,521 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 103,461 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG"), 76,364 by MPM Asset Management Investors BV4 LLC ("AM BV4") 20,408 by MPM BioVentures III, LP. ("BV III"), 303,505 by MPM BioVentures III-QP, LP ("BV III QP"), 25,649 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV III KG"), 9,166 by MPM BioVentures III Parallel Fund, LP ("BV III PF"), 7,215 by MPM Asset Management Investors 2004 BVIII LLC ("AM BV III") and 49,901 by MPM BioVentures Strategic Fund, LP ("BV SF"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC are the direct and indirect general partners of BV IV QP, BV IV KG and AM BV4. Vaughn M. Kailian, Ansbert Gadicke, Luke Evnin, Steven St. Peter, William Greene, James Paul Scopa, Ashley Dombkowski and John VanderVort are the members of the general partner of BV IV QP, BV IV KG and members of AM BV4. MPM BioVentures III GP, L.P. ("BV III GP") and MPM BioVentures III LLC ("BV III LLC") are the direct and indirect general partners of BV III, BV III QP, BV III PF, BV III KG and BV SF. Luke Evnin and Ansbert Gadicke are members of BV III LLC and AM BV III. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
(2)	The securities are held as follows: 361,668 by BV IV QP, 13,933 by BV IV KG and 10,284 by AM BV4. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
(3)	Represent options to purchase CHESS Depository Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock held by CHESS Depositary Nominees Pty Limited, a wholly-owned subsidiary of the Australian Stock Exchange. The CDIs are economically equivalent to shares of common stock of the Issuer on a 1-for-20 basis. CDIs are convertible at the option of the holders thereof into shares of common stock of the Issuer on a 1-for-20 basis.
(4)	Represent shares of common stock of the Issuer issuable upon conversion of the CDIs underlying the related warrant, and excludes fractional shares that would result from the conversion of such CDIs into shares of common stock.
(5)	The securities are held as follows: 184,498 by BV IV QP, 7,108 by BV IV KG and 5,246 by AM BV4. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
(6)	The securities are held as follows: 197,699 by BV IV QP, 7,616 by BV IV KG and 5,622 by AM BV4. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
Â Remarks: SeeÂ FormÂ 3Â forÂ VaughanÂ KailianÂ forÂ additionalÂ membersÂ ofÂ thisÂ jointÂ filing.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.